prostate cancer

New research suggests that analysing the biology of prostate cancer tumours can help doctors identify which patients are most likely to benefit from hormone therapy. The findings could support more personalised treatment decisions, allowing clinicians to target therapy at those most likely to respond rather than applying it universally. The report has drawn attention in medical news coverage.

Doctors are highlighting theranostics, an emerging approach to treating advanced prostate cancer that pairs diagnostic imaging with targeted therapy in a single process. The method allows physicians to detect cancer cells and deliver radiation treatment directly to them, potentially improving outcomes for patients whose disease no longer responds to standard therapies.

Health authorities are reminding men to pay attention to prostate health, covering common conditions such as enlargement and prostate cancer, and the importance of regular screening as men age. The guidance stresses early detection through check-ups and discussing symptoms like urinary changes with a doctor, since risks increase with age and early treatment improves outcomes.